Reviva Pharmaceuticals (RVPH) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine's path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – Cupertino, Calif., August 14, 2025 – Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of ce ...